Diabetes
| Insulins
Diabetes
Insulins

Insulin and Glucagon Coadministration in Type 1 Diabetes Prevents Hypoglycemia without Worsening Hyperglycemia

Bruce W. Bode, MD

ADA 2020 - Poster session

headphones 5 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Hypoglycemia remains the greatest obstacle that prevents insulin-treated patients from attaining acceptable metabolic control and this, in turn, drives long term health consequences.
  • Novel findings have demonstrated that it may be feasible to simultaneously co-administer the peptide hormones within certain plasma concentration conditions, allowing the control of excessive hyperglycemic and hypoglycemic excursions.
  • The co-administered (IV) insulin and glucagon at a fixed molar ratio in subjects with type 1 diabetes during a mixed meal challenge are not showing safety concerns and the treatment was well tolerated by all subjects.
  • A clear mitigation of hypoglycemia risk was observed in all subjects who experienced low blood glucose without worsening control of the post-meal plasma glucose rise.
  • This novel treatment approach is based on an increased appreciation of the complex relationship of the two glucoregulatory peptides, thereby widening the therapeutic window of insulin and mitigating hypoglycemia risk, the greatest fear of patients with diabetes.
  • This approach opens the door to highly impactful yet simplified therapeutic approaches.
Presenting Author
Read more arrow_downward Hide arrow_upward

Bruce W. Bode, MD

Atlanta Diabetes Associates, Atlanta, GA

Disclosures
Read more arrow_downward Hide arrow_upward

B. W. Bode: Advisory Panel; Self; Medtronic, Novo Nordisk A/S, Consultant; Self; Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Research Support; Self; Abbott, Advance, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Insulet Corporation, Janssen Pharmaceuticals, Inc., MannKind Corporation, Medtronic, National Institutes of Health, Nova Biomedical, Novo Nordisk A/S, Provention Bio, Inc., Sanofi, Senseonics, Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., MannKind Corporation, Medtronic, Novo Nordisk A/S, Sanofi, Senseonics, Stock/Shareholder; Self; Aseko.


Feedback